Program
mezigdomide
Also written as “CC-92480”, “Mezigdomide” and “Cohort B1 & B2: KTX-1001+Mezigdomide”.
Its studies are mostly in Multiple Myeloma · Kidney Failure, Chronic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 113 open or running | phase 3since Aug 25, 2022 | Dec 1, 2017 | Jan 10, 2027phase 3 · NCT05519085 |
| K36 Therapeutics | 11 open or running | phase 1since Dec 1, 2022 | Dec 1, 2022 | Dec 31, 2027phase 1 · NCT05651932 |
- Named in Bristol-Myers Squibb’s own pipeline as
mezigdomide
, phase 4, as of Oct 29, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 1, 2017First study: phase 2 study in Multiple MyelomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT03374085 · 200 enrolled · United States, Australia, Belgium and more
- Dec 17, 2018Phase 1 study in Healthy VolunteerBristol-Myers Squibb · NCT03803644 · 56 enrolled · United States
- Dec 24, 2019Phase 1 study in Healthy VolunteerBristol-Myers Squibb · NCT04211545 · 24 enrolled · United States
- Sep 21, 2020Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT04560738 · 8 enrolled · United States
- Apr 7, 2021Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT04839809 · 40 enrolled · United States
- May 20, 2022Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT05389722 · 24 enrolled · United States
- Aug 25, 2022Phase 3 study in RecurrenceBristol-Myers Squibb · NCT05519085 · 810 planned · United States, Argentina, Australia and more
- Sep 21, 2022Phase 3 study in RecurrenceBristol-Myers Squibb · NCT05552976 · 606 enrolled · United States, Argentina, Australia and more
- Dec 1, 2022K36 Therapeutics's first study: phase 1 study in Multiple MyelomaNew to K36 TherapeuticsK36 Therapeutics · NCT05651932 · 165 planned · United States, Canada, France and more
- Jan 23, 2023Phase 1 study in Hepatic ImpairmentBristol-Myers Squibb · NCT05707390 · 32 enrolled · United States
- Mar 12, 2024Phase 1 study in Renal InsufficiencyBristol-Myers Squibb · NCT06318676 · 26 enrolled · United States
- May 16, 2025Phase 2 study in Multiple MyelomaBristol-Myers Squibb · NCT06988488 · 62 planned · United States, Canada, China and more
Ahead
- Jan 10, 2027Primary completion: phase 3 study in RecurrenceBristol-Myers Squibb · NCT05519085
- May 31, 2027Primary completion: phase 2 study in Multiple MyelomaBristol-Myers Squibb · NCT06988488
- Dec 31, 2027Primary completion: phase 1 study in Multiple MyelomaK36 Therapeutics · NCT05651932
TargetBeta
“A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, mezigdomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and target…”NCIt, read by Claude
Other programs on CRBN
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lenalidomiderule | Bristol-Myers Squibb | phase 4 | 109 |
| pomalidomiderule | Bristol-Myers Squibb | phase 4 | 51 |
| golcadomide | Bristol-Myers Squibb | phase 3 | 11 |
| Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506 | Bristol-Myers Squibb | phase 1 | 1 |
| HRS-3738 | Jiangsu HengRui Medicine | phase 1 | 1 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06988488Multiple Myeloma · United States, Canada, China and more | 2 | Recruiting | Bristol-Myers Squibb | May 31, 2027 | 62 |
| NCT06318676Renal Insufficiency · United States | 1 | Completed | Bristol-Myers Squibb | Nov 15, 2024 | 26 |
| NCT05707390Hepatic Impairment · United States | 1 | Completed | Bristol-Myers Squibb | Sep 13, 2023 | 32 |
| NCT05651932Multiple Myeloma · United States, Canada, France and more | 1 | Recruiting | K36 Therapeutics | Dec 31, 2027 | 165 |
| NCT05552976Recurrence · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Sep 28, 2026 | 606 |
| NCT05519085Recurrence · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Jan 10, 2027 | 810 |
| NCT05389722Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Nov 12, 2022 | 24 |
| NCT04839809Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Oct 8, 2021 | 40 |
| NCT04560738Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | May 13, 2021 | 8 |
| NCT04211545Healthy Volunteer · United States | 1 | Completed | Bristol-Myers Squibb | Dec 26, 2019 | 24 |
| NCT03803644Healthy Volunteer · United States | 1 | Completed | Bristol-Myers Squibb | May 28, 2019 | 56 |
| NCT03374085Multiple Myeloma · United States, Australia, Belgium and more | 2 | Terminated | Bristol-Myers Squibb | Aug 20, 2025 | 200 |
How it is read
Names in the registry
- “CC-92480”, 6 entries
- “Mezigdomide”, 4 entries
- “mezigdomide”, 1 entry
- “Cohort B1 & B2: KTX-1001+Mezigdomide”, 1 entry
- “[14C]-CC-92480”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 5 studies
- Kidney Failure, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.